Asset profile
Balipodect (TAK-063)
Small molecule
Evidence outlook · lead readout
NCT02477020 · Schizophrenia
The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.
NCT02477020: The study randomly assigned 164 participants to TAK-063 or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. The clinical primary endpoint was the change in PANSS total score at week 6; TAK-063 showed a larger numerical improvement than placebo, but the difference was not statistically significant (p=0.115), supporting moderate rather than strong evidence.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.